The Accuracy of the Dormotech VLAB During Stable Hypoxia Plateaus
NCT ID: NCT06516809
Last Updated: 2024-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
12 participants
OBSERVATIONAL
2024-05-15
2024-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This was a prospective study with healthy volunteers.
The primary objective of the study was to determine the accuracy of the Dormotech VLAB sensor from saturations from 100 down to 70%. As the primary endpoint, the accuracy of the device during non-motion tests was determined by comparing the pulse oximeter reading during brief, steady-state hypoxia plateaus with a gold-standard measurement of blood oxyhemoglobin saturation (arterial blood sample processed in a multi-wavelength hemoximeter).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Wireless Disposable SpO2 Sensor Hypoxia Testing
NCT06211530
A Clinical Trial to Verify the Accuracy of Seers Technology's Pulse Oximeter (mobiCARE +Pulse, MP100W) in Healthy Volunteers
NCT05895682
SpO2 System Accuracy Testing With Different Sensors
NCT01613222
Prospective Study to Validate the Clinical Accuracy of the Norbert Device to Measure Oxygen Saturation
NCT05685654
Accuracy of Smartwatches in Measuring Oxygen Levels in Patients With Pulmonary Hypertension: A Pilot Study
NCT07311135
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The subjects represent a diverse group in terms of age, height, weight, ethnicity, and skin types, which is beneficial for generalizing findings across different demographics. Subjects span all six types, indicating a wide range of skin types from very fair (Type I) to deeply pigmented dark (Type VI).
This was a prospective study with healthy volunteers.
The primary objective of the study was to determine the accuracy of the Dormotech VLAB sensor from saturations from 100 down to 70%. As the primary endpoint, the accuracy of the device during non-motion tests was determined by comparing the pulse oximeter reading during brief, steady-state hypoxia plateaus with a gold-standard measurement of blood oxyhemoglobin saturation (arterial blood sample processed in a multi-wavelength hemoximeter).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DormoTech Vlab SpO2 sensor
The Dormotech Vlab sensor was applied to one of the subject's forehead. Reference pulse oximeters were applied to the right fingers. Blood gas analysis to determine hemoglobin saturation (SaO2) was performed using an ABL-90 Flex Plus multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). The ABL90 Flex Plus contains factory calibration standards and automatically performs regular quality controls.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is in good health with no evidence of any medical problems.
* Subject is fluent in both written and spoken English.
* Subject has provided informed consent and is willing to comply with the study procedure
Exclusion Criteria
* Subject has known history of heart disease, lung disease, kidney or liver disease.
* Diagnosis of asthma, sleep apnea, or use of CPAP.
* Subject has diabetes.
* Subject has a clotting disorder.
* Subject uses any anticoagulative medication (blood thinner).
* Subject has a hemoglobinopathy or history of anemia, per subject report or the first blood sample, that in the opinion of the investigator, would make them unsuitable for study participation.
* Subject has any other serious systemic illness.
* Subject is a current smoker.
* Subject with any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigators would interfere with the sensors working correctly.
* Subject has a history of fainting or vasovagal response.
* Subject has a history of sensitivity to local anesthesia
* Subject has a diagnosis of Raynaud's disease
* Subject has claustrophobia
* Subject has unacceptable collateral circulation based on exam by the investigator (Allen's test).
* Subject is pregnant, lactating or trying to get pregnant.
* Subject is unable or unwilling to provide informed consent or is unable or unwilling to comply with study procedures.
* Subject has any other condition, which in the opinion of the investigators would make them unsuitable for the study.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dormotech Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregg Stratmann, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Vital Signs Research Group, San Francisco, CA.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vital Signs Research Group
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VLAB_SpO2_C_T_1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.